

POSTER PRESENTATION

Open Access

Cell therapy in renal ischemia/reperfusion experimental model using recombinant G-CSF

Vinicius Correa Rodrigues^{1*}, Isabela Bastos Binotti Araújo¹, Rosiane Ervati², Sônia da Penha Silva Oliveira², Breno Valentim Nogueira²

From 5th Congress of the Brazilian Biotechnology Society (SBBIOTEC) Florianópolis, Brazil. 10-14 November 2013

Introduction

The colony stimulating factor granulocyte (G-CSF) is a glycoprotein capable of promoting the survival, proliferation and differentiation of hematopoietic cells. Studies demonstrate the cytoprotective action of G-CSF against renal injury by ischemia/reperfusion injury in murine models. But the literature is still controversial in relation to the risk of worsening renal function after use G-CSF, which motivated the study to elucidate possible interference on the renal function of the treated animals.

Objective

Evaluate the renal function of rats after treatment with G-CSF at different doses of the drug.

Methods

Male Wistar rats (n = 18), 200g approx. (CEUA050/2013), divided into 3 groups (6 animals each) : control group (C) 5% glucose solution (solvent) groups treated with G-CSF at a dose of 10 (G10) and 50 (G50) mg / kg / per 5 days. After treatment, the rats were placed in metabolic cages for urine collection and obtaining urine volume. Values were obtained from creatinine, proteinuria, urea and number of circulating leukocytes. The results were expressed as mean \pm SEM. The averages of values between groups were calculated using one - way ANOVA followed by post hoc Fisher for comparison between different groups.

Results

A significant increase in the number of circulating leukocytes in animals treated with G-CSF (C = 9687 ± 899 / mm³; = 14375 ± 1967 / mm³ G10, and G50 = 19670 ± 1663 / mm³, p < 0.05). There was not a significant increase

in urine volume after 24 hours treatment with G-CSF. There was no significant difference between the values of creatinine clearance, proteinuria and Urea, among groups C, G10 and G50.

Conclusion

There was no impairment of renal function in animals treated at doses of 10 and 50 mg / kg / per 5 days.

Financial support: FAPES

Authors' details

¹PG Biotecnologia, UFES, Vitoria, Brasil. ²Departamento de Morfologia, UFES, Vitoria, Brasil.

Published: 1 October 2014

References

1. Stokman G, Leemans JC, Claessen N, Weening JJ, Florquin S: Hematopoietic stem cell mobilization therapy accelerates recovery of renal function independent of stem cell contribution. *J Am Soc Nephrol* 2005, **16**(6):1684-1692.
2. Nishida M, Hamaoka K: How does GCSF act on the kidney during acute tubular injury? *Nephron Exp Nephrol* 2006, **104**(4):e123-e128.
3. Verweij M, Sluiter W, van den Engel S, Jansen E, Ijzermans JN, de Bruin RW: Altered Mitochondrial Functioning Induced by Preoperative Fasting May Underlie Protection Against Renal Ischemia/Reperfusion Injury. *Journal of Cellular Biochemistry* 2013, **114**(1):230-237.

doi:10.1186/1753-6561-8-S4-P25

Cite this article as: Rodrigues et al.: Cell therapy in renal ischemia/reperfusion experimental model using recombinant G-CSF. *BMC Proceedings* 2014 **8**(Suppl 4):P25.

¹PG Biotecnologia, UFES, Vitoria, Brasil

Full list of author information is available at the end of the article